
Marzia Cirri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8925457/publications.pdf Version: 2024-02-01



MADZIA CIDDI

#	Article	IF	CITATIONS
1	Role of Cyclodextrins and Drug Solid State Properties on Flufenamic Acid Dissolution Performance from Tablets. Pharmaceutics, 2022, 14, 284.	2.0	6
2	Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review. Marine Drugs, 2022, 20, 335.	2.2	40
3	Evaluation and Comparison of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Vectors to Develop Hydrochlorothiazide Effective and Safe Pediatric Oral Liquid Formulations. Pharmaceutics, 2021, 13, 437.	2.0	53
4	Development and microbiological evaluation of chitosan and chitosan-alginate microspheres for vaginal administration of metronidazole. International Journal of Pharmaceutics, 2021, 598, 120375.	2.6	27
5	Improvement of Butamben Anesthetic Efficacy by the Development of Deformable Liposomes Bearing the Drug as Cyclodextrin Complex. Pharmaceutics, 2021, 13, 872.	2.0	8
6	Development of a Cyclodextrin-Based Mucoadhesive-Thermosensitive In Situ Gel for Clonazepam Intranasal Delivery. Pharmaceutics, 2021, 13, 969.	2.0	20
7	Combined Use of Cyclodextrins and Amino Acids for the Development of Cefixime Oral Solutions for Pediatric Use. Pharmaceutics, 2021, 13, 1923.	2.0	7
8	Amine- and Amino Acid-Based Compounds as Carbonic Anhydrase Activators. Molecules, 2021, 26, 7331.	1.7	9
9	Development of a stable oral pediatric solution of hydrochlorothiazide by the combined use of cyclodextrins and hydrophilic polymers. International Journal of Pharmaceutics, 2020, 587, 119692.	2.6	8
10	Development and Characterization of Liquisolid Tablets Based on Mesoporous Clays or Silicas for Improving Glyburide Dissolution. Pharmaceutics, 2020, 12, 503.	2.0	9
11	Tablets of "Hydrochlorothiazide in Cyclodextrin in Nanoclay― A New Nanohybrid System with Enhanced Dissolution Properties. Pharmaceutics, 2020, 12, 104.	2.0	10
12	β-Sitosterol Loaded Nanostructured Lipid Carrier: Physical and Oxidative Stability, In Vitro Simulated Digestion and Hypocholesterolemic Activity. Pharmaceutics, 2020, 12, 386.	2.0	13
13	Characterization and evaluation of different mesoporous silica kinds as carriers for the development of effective oral dosage forms of glibenclamide. International Journal of Pharmaceutics, 2019, 563, 43-52.	2.6	18
14	Characterization and microbiological evaluation of chitosan-alginate microspheres for cefixime vaginal administration. Carbohydrate Polymers, 2018, 192, 176-183.	5.1	32
15	Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. Drug Delivery, 2018, 25, 1910-1921.	2.5	86
16	Combined Approach of Cyclodextrin Complexationand Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide. Pharmaceutics, 2018, 10, 287.	2.0	17
17	Improving the therapeutic efficacy of prilocaine by PLGA microparticles: Preparation, characterization and in vivo evaluation. International Journal of Pharmaceutics, 2018, 547, 24-30.	2.6	24
18	A preliminary study for the development and optimization by experimental design of an in vitro method for prediction of drug buccal absorption. International Journal of Pharmaceutics, 2018, 547, 530-536.	2.6	9

MARZIA CIRRI

#	Article	IF	CITATIONS
19	Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles―formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. International Journal of Pharmaceutics, 2017, 521, 73-83.	2.6	50
20	Development and characterization of fast dissolving tablets of oxaprozin based on hybrid systems of the drug with cyclodextrins and nanoclays. International Journal of Pharmaceutics, 2017, 531, 640-649.	2.6	12
21	Development of cyclodextrin hydrogels for vaginal delivery of dehydroepiandrosterone. Journal of Pharmacy and Pharmacology, 2016, 68, 762-771.	1.2	13
22	Development and characterization of fast-dissolving tablet formulations of glyburide based on solid self-microemulsifying systems. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 104, 19-29.	2.0	23
23	Polymeric mucoadhesive tablets for topical or systemic buccal delivery of clonazepam: Effect of cyclodextrin complexation. Carbohydrate Polymers, 2016, 152, 755-763.	5.1	33
24	Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-AŸ-cyclodextrin and I -arginine aimed to improve the drug solubility. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 350-358.	1.4	42
25	Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation. International Journal of Pharmaceutics, 2016, 515, 684-691.	2.6	44
26	Comparative evaluation of polymeric and waxy microspheres for combined colon delivery of ascorbic acid and ketoprofen. International Journal of Pharmaceutics, 2015, 485, 365-373.	2.6	30
27	Combined use of bile acids and aminoacids to improve permeation properties of acyclovir. International Journal of Pharmaceutics, 2015, 490, 351-359.	2.6	7
28	Development of liposomal and microemulsion formulations for transdermal delivery of clonazepam: Effect of randomly methylated β-cyclodextrin. International Journal of Pharmaceutics, 2014, 475, 306-314.	2.6	47
29	Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Delivery, 2012, 19, 354-361.	2.5	106
30	Development of a new delivery system consisting in "drug – in cyclodextrin – in nanostructured lipid carriers―for ketoprofen topical delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 46-53.	2.0	123
31	Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-12-cyclodextrin-PVP complex. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 67-75.	2.0	99
32	New solid self-microemulsifying systems to enhance dissolution rate of poorly water soluble drugs. Pharmaceutical Development and Technology, 2012, 17, 277-284.	1.1	46
33	Influence of cross-linking agent type and chitosan content on the performance of pectinate-chitosan beads aimed for colon-specific drug delivery. Drug Development and Industrial Pharmacy, 2012, 38, 1142-1151.	0.9	28
34	Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 385-393.	2.0	43
35	Mixture experiment methods in the development and optimization of microemulsion formulations. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 610-617.	1.4	44
36	Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation. Journal of Pharmaceutical Sciences, 2010, 99, 3019-3029.	1.6	46

MARZIA CIRRI

#	Article	IF	CITATIONS
37	Influence of the preparation method on the physical–chemical properties of ketoprofen–cyclodextrin–phosphatidylcholine ternary systems. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 690-694.	1.4	31
38	Comparative study of oxaprozin complexation with natural and chemically-modified cyclodextrins in solution and in the solid state. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2009, 63, 17-25.	1.6	37
39	Physical–chemical characterization of binary and ternary systems of ketoprofen with cyclodextrins and phospholipids. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 683-689.	1.4	20
40	Development of Glyburide Fast-Dissolving Tablets Based on the Combined Use of Cyclodextrins and Polymers. Drug Development and Industrial Pharmacy, 2009, 35, 73-82.	0.9	21
41	Microspheres for colonic delivery of ketoprofen-hydroxypropyl-β-cyclodextrin complex. European Journal of Pharmaceutical Sciences, 2008, 34, 1-11.	1.9	57
42	Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 303-309.	2.0	86
43	Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 508-518.	2.0	93
44	Dissolution and Permeation Properties of Naproxen From Solid-State Systems With Chitosan. Drug Delivery, 2008, 15, 303-312.	2.5	18
45	Fast-Dissolving Tablets of Clyburide Based on Ternary Solid Dispersions with PEG 6000 and Surfactants. Drug Delivery, 2007, 14, 247-255.	2.5	25
46	Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. International Journal of Pharmaceutics, 2007, 340, 84-91.	2.6	59
47	Physical–chemical characterization of binary systems of metformin hydrochloride with triacetyl-β-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 480-486.	1.4	44
48	Physicochemical characterization of drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2007, 57, 223-231.	1.6	28
49	Development of a sustained-release matrix tablet formulation of DHEA as ternary complex with α-cyclodextrin and glycine. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2007, 57, 699-704.	1.6	2
50	The influence of chitosan on cyclodextrin complexing and solubilizing abilities towards drugs. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2007, 59, 307-313.	1.6	17
51	Study of formulation variables influencing the drug release rate from matrix tablets by experimental design. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 77-84.	2.0	55
52	Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 241-246.	2.0	48
53	Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 126-131.	1.4	63
54	Differential scanning calorimetry as a screening technique in compatibility studies of DHEA extended release formulations. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 3-10.	1.4	41

MARZIA CIRRI

#	Article	IF	CITATIONS
55	Development and evaluation of an in vitro method for prediction of human drug absorption. European Journal of Pharmaceutical Sciences, 2006, 27, 346-353.	1.9	39
56	Development and evaluation of an in vitro method for prediction of human drug absorption. European Journal of Pharmaceutical Sciences, 2006, 27, 354-362.	1.9	88
57	Interaction of naproxen with ionic cyclodextrins in aqueous solution and in the solid state. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 987-994.	1.4	40
58	Determination of stability constant values of flurbiprofen–cyclodextrin complexes using different techniques. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 995-1002.	1.4	43
59	Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 65-71.	1.4	47
60	Comparative Study on Triclosan Interactions in Solution and in the Solid State with Natural and Chemically Modified Cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2005, 53, 77-83.	1.6	25
61	Development of Fast-Dissolving Tablets of Flurbiprofen-Cyclodextrin Complexes. Drug Development and Industrial Pharmacy, 2005, 31, 697-707.	0.9	45
62	Solid-state characterization and dissolution properties of Naproxen–Arginine–Hydroxypropyl-β-cyclodextrin ternary system. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 99-106.	2.0	83
63	Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Il Farmaco, 2005, 60, 913-918.	0.9	66
64	Characterization and Dissolution Properties of Ketoprofen in Binary and Ternary Solid Dispersions with Polyethylene Glycol and Surfactants. Drug Development and Industrial Pharmacy, 2005, 31, 425-434.	0.9	43
65	Solid-state characterization of glyburide-cyclodextrin co-ground products. Journal of Thermal Analysis and Calorimetry, 2004, 77, 413-422.	2.0	22
66	Characterization of the solid phases of paracetamol and fenamates at equilibrium in saturated solutions. Journal of Thermal Analysis and Calorimetry, 2004, 77, 541-554.	2.0	27
67	Photostability studies on nicardipine–cyclodextrin complexes by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 267-275.	1.4	29
68	Influence of solvent composition on the solid phase at equilibrium with saturated solutions of quinolones in different solvent mixtures. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 715-726.	1.4	12
69	Characterization of Ibuproxam Binary and Ternary Dispersions with Hydrophilic Carriers. Drug Development and Industrial Pharmacy, 2004, 30, 65-74.	0.9	44
70	Development of Enteric-coated Timed-release Matrix Tablets for Colon Targeting. Journal of Drug Targeting, 2004, 12, 607-612.	2.1	43
71	Development and Evaluation of Glyburide Fast Dissolving Tablets Using Solid Dispersion Technique. Drug Development and Industrial Pharmacy, 2004, 30, 525-534.	0.9	77
72	Title is missing!. Journal of Thermal Analysis and Calorimetry, 2003, 73, 635-646.	2.0	50

Marzia Cirri

#	Article	IF	CITATIONS
73	Enhancement of Dehydroepiandrosterone Solubility and Bioavailability by Ternary Complexation with α yclodextrin and Glycine. Journal of Pharmaceutical Sciences, 2003, 92, 2177-2184.	1.6	31
74	Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and aminoacids. International Journal of Pharmaceutics, 2003, 260, 293-302.	2.6	105
75	Development of Enteric-coated Pectin-based Matrix Tablets for Colonic Delivery of Theophylline. Journal of Drug Targeting, 2003, 11, 365-371.	2.1	54
76	Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. Journal of Pharmaceutical and Biomedical Analysis, 2002, 30, 227-237.	1.4	74